Tin tức & Cập nhật

Chỉ hiển thị Multimedia
Ripretinib improves survival in advanced gastrointestinal stromal tumours

Ripretinib improves survival in advanced gastrointestinal stromal tumours

11 Apr 2023 bởiStephen Padilla

Treatment with ripretinib provides a prolonged clinical and radiological benefit in patients with advanced gastrointestinal stromal tumours (GIST) within the expanded access program (EAP) in the UK, as shown in a study presented at the ESMO Sarcoma and Rare Cancers Congress 2023 in Lugano, Switzerland.

11 Apr 2023
Watch-and-wait approach for rectal cancer may boost potential of maintaining good quality of life

Watch-and-wait approach for rectal cancer may boost potential of maintaining good quality of life

03 Apr 2023

Patients with rectal cancer who are monitored using a watch-and-wait approach are more likely to have a good quality of life, whereas those who undergo surgery appear to experience deterioration in quality of life and functional outcome, as reported in a study.

03 Apr 2023
Dysmenorrhoea, urinary pain predict deep infiltrating endometriosis

Dysmenorrhoea, urinary pain predict deep infiltrating endometriosis

28 Mar 2023 bởiStephen Padilla

Severe dysmenorrhoea, pain related to urinary and gastrointestinal tracts, higher fertility desire and infertility rate are all associated with deep infiltrating endometriosis, according to a Singapore study. On the other hand, heavy menstrual bleeding is predictive of adenomyosis.

28 Mar 2023
Polysaccharide hemostatic powder shows promise for peptic ulcer bleeding

Polysaccharide hemostatic powder shows promise for peptic ulcer bleeding

27 Mar 2023

In the initial endoscopic treatment of peptic ulcer bleeding, the use of polysaccharide hemostatic powder appears to be not less efficacious than conventional treatment, according to a study.

27 Mar 2023
Ondansetron shows potential in irritable bowel syndrome with diarrhoea

Ondansetron shows potential in irritable bowel syndrome with diarrhoea

27 Mar 2023

A study on titrated ondansetron for the treatment of irritable bowel syndrome with diarrhoea (IBS-D) has fallen short of meeting the endpoint due to being underpowered. However, when data from this study and two others were pooled in a meta-analysis, ondansetron appears to yield significant improvements in the composite endpoint set by the Food and Drug Administration (FDA), namely stool consistency and urgency.

27 Mar 2023